美股市场个股详情
RARE Ultragenyx Pharmaceutical
- 44.240
- +0.390+0.89%
收盘价 04/26 16:00 (美东)
- 43.310
- -0.930-2.10%
盘后 16:05 (美东)
36.43亿总市值-5362市盈率TTM
44.575最高价43.710最低价45.04万股成交量44.160今开43.850昨收1992.32万成交额0.62%换手率亏损市盈率(静)8233.57万总股本54.98052周最高13.23市净率31.93亿流通值31.52052周最低--股息TTM7217.17万流通股179.647历史最高--股息率TTM1.97%振幅31.520历史最低44.232平均价1股每手
关于Ultragenyx Pharmaceutical公司
Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。 它识别、收购、开发和商业化用于治疗严重罕见和超罕见疾病的新产品，重点是严重的、使人衰弱的遗传疾病。 该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。 Crysvita 适用于治疗成人和 1 岁及以上儿童患者的 X 连锁低磷血症 (XLH)。 Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。
公司介绍
公司代码RARE
公司名称Ultragenyx Pharmaceutical
上市日期2014/01/31
发行价格21.00
成立日期2010
CEODr. Emil D. Kakkis, M.D.,PhD
所属市场纳斯达克
员工数量1276
证券类型海外普通股
年结日12-31
公司地址60 Leveroni Court
城市Novato
省份加利福尼亚州
国家美国
邮编94949
电话1-415-483-8800
董事高管
- 姓名
- 职务
- 年薪
- Dr. Emil D. Kakkis, M.D.,PhD
- Director, President, Chief Executive Officer
- 1214.03万
- Karah Parschauer
- Chief Legal Officer and Executive Vice President
- --
- John Richard Pinion, II
- Chief Quality Officer and Executive Vice President, Translational Sciences
- 370.65万
- Theodore A. Huizenga
- Senior Vice President, Corporate Controller and Chief Accounting Officer
- --
- Dr. Eric Crombez, M.D.
- Executive Vice President and Chief Medical Officer
- --
- Dennis Karl Huang
- Chief Technical Operations Officer and Executive Vice President, Gene Therapy Operations
- --
- Howard Horn
- Chief Financial Officer and Executive Vice President, Corporate Strategy
- --
- Thomas R. Kassberg
- Chief Business Officer and Executive Vice President
- 233.17万
- Erik Harris
- Chief Commercial Officer and Executive Vice President
- 374.86万
- Daniel G. Welch
- Chairman of the Board
- 49.94万
- Dr. Shehnaaz Suliman, M.D.
- Independent Director
- 46.64万
- Dr. Corsee Dating Sanders, PhD
- Independent Director
- 46.58万
- Michael A. Narachi
- Independent Director
- 48.13万
- Dr. Deborah L. Dunsire,M.D.
- Independent Director
- 46.22万
- Dr. Amrit Ray
- Independent Director
- 124.16万
- Matthew K. Fust
- Independent Director
- 47.82万
- Dr. Camille L. Bedrosian,M.D.
- Strategic Development Advisor
- 375.53万
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅